ShareThis Page
Health

Medications for blood pressure and heart failure recalled

Tawnya Panizzi
| Wednesday, Jan. 2, 2019, 9:48 a.m.
Certain blood pressure medication is being recalled for impurities on Jan. 2, 2019.
FDA.gov
Certain blood pressure medication is being recalled for impurities on Jan. 2, 2019.

A blood pressure medication is being recalled, according to a U.S. Food and Drug Administration report, but patients prescribed the drug are advised to continue taking it until they talk to their doctor.

Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan Tablets USP.

The medicines are used to control blood pressure and treat heart problems.

The advisory was issued because a trace amount of the impurity NDEA, classified as a probable carcinogen, was detected in the bottled medication.

The company hasn’t received any reports of ill patients related to the drugs.

The FDA alert said patients should keep taking the medicine until they talk with their doctor because of the increased risk of stopping prescribed medication without alternative treatment.

Patients can check their medicine against a complete recalled list on the FDA website.

For more, call Aurobindo Pharma USA Inc. at 1-866-850-2876, option 2 or email pvg@aurobindousa.com.

Tawnya Panizzi is a Tribune-Review staff writer. You can contact Tawnya at 412-782-2121, ext. 2, tpanizzi@tribweb.com or via Twitter @tawnyatrib.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me